StockData
Rein Therapeutics, Inc. logo

Rein Therapeutics, Inc. (RNTX) stock

RNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.36−0.04 (-10.90%)

Close on Nov 17, 2026Market cap $30.75MP/E –Yield 0.00%

Rein Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Rein Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $10.39M, down 27.8% year over year. For fiscal 2025 it was $11.03M, down 22.6% from the year before. Over ten years it grew 3.5% a year on average. The highest annual figure on record is $18.45M in fiscal 2018.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$11.03M-22.6%
FY2024Dec 31, 2024$14.25M+257.0%
FY2023Dec 31, 2023$3.99M-77.8%
FY2022Dec 31, 2022$17.97M+5.6%
FY2021Dec 31, 2021$17.01M+52.3%
FY2020Dec 31, 2020$11.17M-36.8%
FY2019Dec 31, 2019$17.66M-4.3%
FY2018Dec 31, 2018$18.45M+29.6%
FY2017Dec 31, 2017$14.24M+38.6%
FY2016Dec 31, 2016$10.28M+31.2%
FY2015Dec 31, 2015$7.83M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.64M-15.2%
Q1 FY2026Mar 31, 2026$3.07M+0.6%
Q4 FY2025Dec 31, 2025$2.00M-39.8%
Q3 FY2025Sep 30, 2025$1.68M-54.8%
Q2 FY2025Jun 30, 2025$4.29M+14.7%
Q1 FY2025Mar 31, 2025$3.05M-11.8%
Q4 FY2024Dec 31, 2024$3.32M+68.5%
Q3 FY2024Sep 30, 2024$3.72M+16818.2%
Q2 FY2024Jun 30, 2024$3.74M+1900.5%
Q1 FY2024Mar 31, 2024$3.46M+91.3%
Q4 FY2023Dec 31, 2023$1.97M-17.9%
Q3 FY2023Sep 30, 2023$22.00K-99.5%
Q2 FY2023Jun 30, 2023$187.00K-96.6%
Q1 FY2023Mar 31, 2023$1.81M-69.3%
Q4 FY2022Dec 31, 2022$2.40M-47.3%
Q3 FY2022Sep 30, 2022$4.24M-0.9%
Q2 FY2022Jun 30, 2022$5.43M+41.0%
Q1 FY2022Mar 31, 2022$5.89M+36.5%
Q4 FY2021Dec 31, 2021$4.56M+136.9%
Q3 FY2021Sep 30, 2021$4.28M+59.4%
Q2 FY2021Jun 30, 2021$3.85M+54.9%
Q1 FY2021Mar 31, 2021$4.32M+6.1%
Q4 FY2020Dec 31, 2020$1.93M-59.1%
Q3 FY2020Sep 30, 2020$2.68M-40.0%
Q2 FY2020Jun 30, 2020$2.49M-42.2%
Q1 FY2020Mar 31, 2020$4.07M-2.5%
Q4 FY2019Dec 31, 2019$4.71M+18.9%
Q3 FY2019Sep 30, 2019$4.48M+3.6%
Q2 FY2019Jun 30, 2019$4.31M-19.1%
Q1 FY2019Mar 31, 2019$4.17M-13.9%
Q4 FY2018Dec 31, 2018$3.96M-8.1%
Q3 FY2018Sep 30, 2018$4.32M+13.0%
Q2 FY2018Jun 30, 2018$5.32M+68.3%
Q1 FY2018Mar 31, 2018$4.85M+64.7%
Q4 FY2017Dec 31, 2017$4.31M+39.4%
Q3 FY2017Sep 30, 2017$3.83M+46.8%
Q2 FY2017Jun 30, 2017$3.16M–
Q1 FY2017Mar 31, 2017$2.94M–
Q4 FY2016Dec 31, 2016$3.09M–
Q3 FY2016Sep 30, 2016$2.61M–

More Rein Therapeutics figures

See a number that looks wrong?